De_Monitor
Nov 14, 8:26 AM
$PHVS is shaping up to be one of the most compelling late-stage HAE stories. Its once-daily oral deucrictibant XR cut HAE attacks by 83% versus placebo in Phase 3 CHAPTER-3 (87% in Type 1/2), meeting the primary and every secondary efficacy endpoint with statistical significance. With a generally well-tolerated profile, the prospect of highly effective, injection-free prevention is genuinely exciting.
And the momentum doesn’t stop there. Deucrictibant IR delivered a median time to onset of symptom relief of just 1.28 hours in RAPIDe-3 and is already under FDA review, with a decision date of April 23, 2027. Add €283M in cash at September 30, upcoming CREAATE data in Q1 2027, and a planned prophylaxis filing in H1 2027. Approval is not guaranteed, but with two oral formulations and multiple major catalysts ahead, the
$PHVS bull case keeps getting stronger!
0 replies